A group of physicians and Prader-Willi syndrome experts notified clinicians about potential safety concerns tied to Neurocrine Biosciences’ newly approved Vykat XR (sparсaple?) through the FDA’s adverse event monitoring systems. They cited seven deaths and more than 100 reports of serious side effects, mostly hospitalizations for swelling, respiratory, and heart complications. The experts emphasized the deaths and severe events have not been definitively linked to Vykat XR. They also said the communications are intended to increase awareness of risks when clinicians start patients on the treatment. For biotech stakeholders, the update highlights the operational reality of post-approval pharmacovigilance after accelerated timelines for rare-disease therapies—especially when adverse events are clustered by system (respiratory and cardiovascular).